Clinical use of recombinant FVIIa (rFVIIa)

Transfusion Science

Volumn 19, Issue 2, 1998, Pages 163-176

  Hedner, Ulla ^a   Ingerslev, Jørgen ^b  

^a NOVO NORDISK A S   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 7A; DICOUMAROL; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; WARFARIN;

ANTIBODY PRODUCTION; BLEEDING; BLOOD CLOTTING FACTOR 7 DEFICIENCY; CLINICAL TRIAL; DISSEMINATED INTRAVASCULAR CLOTTING; DOG; HEMOPHILIA; HEMOSTASIS; HUMAN; LIVER DISEASE; META ANALYSIS; MUSCLE NECROSIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PEROPERATIVE COMPLICATION; POSTOPERATIVE COMPLICATION; PROTHROMBIN TIME; RABBIT; REVIEW; THROMBOCYTE ANOMALY; THROMBOSIS; VON WILLEBRAND DISEASE;

EID: 0346401265     PISSN: 09553886     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-3886(98)00026-5     Document Type: Article

References (58)

1. Rapaport SI, Rao LVM: The tissue factor pathway: how it has become a "prima ballerina". Thromb Hemostas 1995; 74:7-17.
2. Wilcox JN, Smith KM, Schwartz SM, Gordon D: Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86:2839-2843.
3. Wildgoose P, Nemerson Y, Hansen LL, Nielsen FE, Glazer S, Hedner U: Measurement of basal levels of factor VIIa in hemophilia A and B patients. Blood 1992; 80:25-28.
4. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC: Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81:734-744.
5. Bauer KA, Mannucci PM, Gringeri A, et al.: Factor IXa-factor VIIIa-cell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo. Blood 1992; 79:2039-2047.
6. Hoffman M, Monroe DM, Oliver JA, Roberts HR: Factor IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. Blood 1995; 86:1794-1801.
7. Rao LVM, Rapaport SI: Factor VIIa-catalyzed activation of factor X independent of tissue factor: its possible significance for control of hemophilic bleeding by infused factor VIIa. Blood 1990; 75:1069-1073.
8. Hoffman M, Monroe DM, Roberts HR: Human monocytes support factor X activation by factor VIIa independent of tissue factor: implications or the therapeutic mechanism of high-dose factor VIIa in hemophilia. Blood 1994; 83(3):38-42.
9. Monroe DM, Hoffman M, Oliver JA, Roberts HR: Platelet activity of high-dose factor VIIa is independent of tissue factor. Brit J Haemat 1997; 99:542-547.
10. Sjamsoedin JM, Leijnen L, Mauser-Bunschoten EP, et al.: The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. N Engl J Med 1981; 305:717-721.
11. Lusher JM, Shapiro SS, Palascak JE, Rao AV, Levine PH, Blatt PM: Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII. N Engl J Med 1980; 303:421-425.
12. Lusher JM: Thrombogenicity associated with factor IX complex concentrates. Semin Hematol 1991; 128:3-5.
13. White GC, Roberts HR, Kingdon HS, Lundblad RL: Prothrombin complex concentrates: potentially thrombogenic materials and cles to the Mechanism of Thrombosis in vivo. Blood 1977; 49:159-170.
14. Hedner U, Kisiel W: Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. J Clin Invest 1983; 71:1836-1841.
15. Hedner U, Bjoern S, Bernvil SS, Tengborn L, Stigendahl L: Clinical experience with human plasma-derived factor VIIa in patients with hemophilia A and high titer inhibitors. Hemostasis 1989; 19:335-343.
16. Thim L, Bjoern S, Christensen M, et al.: Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Biochemistry 1988; 27:7785-7793
17. Bjoern S, Foster DC, Thim L, et al.: Human plasma and recombinant factor VI:characterization of O-glysylation at serine 52 and 60 and effects of site directed mutagenesis of serine 52 to alanine. J Biol Chem 1991; 266:11051-11057.
18. Hedner U, Ljungberg J, Lund-Hansen T: Comparison of the effect of plasmaderived and recombinant human FVIIa in vitto and in a rabbit model. Blood Coagul Fibrinolysis 1990; 1:145-151.
19. Brinkhous KM, Hedner U, Garris JB, Diness V, Read MS: Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A hemophilia B and von Willebrand disease. Proc Natl Acad Sci USA 1989; 86:1382-1386.
20. Beeby TL, Chasseaud LF, Taylor T, Thomsen MK: Distribution of the recombinant coagulation factor 1251-rFVIIa in rats. Thromb Haemostas 1993; 70:465-468.
21. Thomsen MK, Wildgoose P, Nilsson P, Hedner U: Accumulation of recombinant factor VIIa in rat bone: importance of the Gla-domain and relevance to factor IX another vitamin K-dependent clotting factor. Pharmacol Toxicol 1993; 73:127-132.
22. Hedner U, Nilsson IM, Bergentz S-E.: Various prothrombin complex concentrates and their effect on coagulation and fibrinolysis in vivo. Thromb Hemostas 1976; 35:386-395.
23. Diness V: rFVIIa in an endotoxin model and in a Wessler model, in Hedner U, Roberts HR (eds): New Aspects of Hemophilia Treatment. 2nd Symposium on New Aspects of Hemophilia Treatment, Copenhagen, 1991, 147-150.
24. Diness V, Bregengaard C, Frhardtsen F, Hedner U: Recombinant human factor VIIa (rFVIIa) in a rabbit stasis model. Thromb Res 1992; 67:233-241.
25. Lusher J, Ingerslev J, Roberts HR, Hedner U: Clinical experience with recombinant factor VIIa. A review. Blood Coag Fibrinolys, 1998; 9:119-128.
26. Macik BG, Lindley CM, Lusher J, et al.: Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rFVIIa): results of a Phase I study. Transfusion 1993; 33:878.
27. Cooper HA, Hoots WK, Shapiro A: Comparison of two doses of recombinant factor VIIa (rFVIIa) for producing hemostasis during and after surgery in patients (PTS) with hemophilia A or B and inhibitors and PTS with acquired inhibitors. Thromb Hemostas 1997; (Suppl) 167, abstract SC-680.
28. Key NS: Efficacy of recombinant factor VIIa (rFVIIa) when administered in the home to control joint muscle and mucocutaneous bleeds in hemophiliacs with inhibitors. Thromb Haemostas 1997; (Suppl) p. 51 abstract PS-206.
29. Glazer S, Hedner U, Falch JF: Clinical update on the use of recombinant factor VII, in Inhibitors to Coagulation Factors, Aledort LM, Hoyer LW, Lusher JM, Reisner HM, White GC, (eds), Advances in Experimental Medicine and Biology. New York, Plenum Press, 1995; 386:163-174.
30. Gringeri A, Santagostino E, Mannucci PM: Failure of recombinant activated factor VII during surgery in a hemophilias with high-titer factor VIII antibody. Hemostasis 1991; 21:1-4.
31. Hedner U, Glazer S, Pingel K, et al.: Successful use of recombinant factor Viia in patient with severe hemophilia A during synovectomy. Lancet 1988; 2(8621):1193
32. Schulman S, Bech Jensen M, Varon D, Keller N, Heim M, Martinowitz U: Feasibility of using recombinant factor VIIa in continuous infusion. Thromb Hemostas 1996; 75:432-436.
33. Stein SF, Duncan A, Cutler D, Glazer S: Disseminated intravascular coagulation (DIC) in a hemophiliac treated with recombinant factor VIIa. Blood 1990; 76:438a.
34. Nicolaisen EM, Hansen LL, Poulsen F, Glazer S, Hedner U: Immunological aspects of recombinant factor VIIa (rFVIIa) in clinical use. Thromb Hemostas 1996; 76 (2):200-204.
35. Schmidt ML, Smith HE, Gamerman S, DiMichele D, Glazer G, Scott JP: Prolonged recombinant activated factor FVII treatment for severe bleeding in factor IX deficient patient with an inhibitor. Br J Hematology 1991; 78:460-463.
36. Macik BG, Hohneker J, Roberts HR, Griffin AM: Use of recombinant activated factor VII for treatment of a retropharyngeal hemorrhage in a hemophilic patient with a high titer inhibitor. Am J Hematol 1989; 32:232-234.
37. Tengborn L, Kjellman B, Elf strand PO, Baagenholm T: Recombinant factor VIIa in an infant with haemophilia A and inhibitors. Acta Paediatr 1992; 81:566-567.
38. Majumdar G, Savidge GF: Recombinant factor VIIa for intracranial haemorrhage in a Jehovah's Witness with severe Haemophilia A and factor VIII inhibitors. Blood Coagul Fibrinolysis 1993; 4:1031-1033.
39. Schmidt ML, Gamerman S, Smith HE, Scott JP, DiMichele DM: Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia A patients with inhibitors. Am J Hematol 1994; 47:36-40.
40. Rice KM, Savidge GF: NovoSeven in central nervous system bleeds. Haemostasis 1996; 26:131-134 (Suppl 1).
41. Schulman S, Lindstedt M, Alberts KA, Agren P-H: Recombinant factor VIIa in multiple surgery. Thromb Haemostas 1994; 71(1):154-161.
42. Smith OP, Hann IM: rFVIIa therapy to secure haemostasis during central line insertion in children with high-responding FVIII inhibitors. Brit J Haematol 1996; 92:1002-1004.
43. Bell BA, Birch K, Glazer S: Experience with recombinant factor VIIa in an infant hemophiliac with inhibitors to FVIII:C undergoing emergency central line placement. A case report. Am J Pediatr Hematol Oncol 1993; 15:77-79.
44. Ingerslev J, Feldsted M, Sindet-Pedersen S: Control of haemostasis by recombinant factor VIIa in a hemophilia A patient with inhibitors during major oral surgery. Lancet 1991; 338:831-832.
45. Stiltjes N, Onnoughene N, Vassilieff D, Sultan Y: Failure of recombinant factor VIIa to control surgical bleeding in a severe hemophilia A patient with an inhibitor and possible DIC. Thromb Hemostas 1997; (Suppl. Abstract book), Abstr PS-202.
46. Majumdar G, Phillips JK, Lavallee H, Savidge GF: Acquired haemophilia in association with Type III von Willebrand's disease: successful treatment with high purity von Willebrand's factor and recombinant factor VIIa. Blood Coagul Fibrinolysis 1993; 4:1035-1037.
47. Stein J, Ratnoff OD: An inhibitor of antihemophilic factor (factor VIII) in an 18-month-old nonhemophilic child. Am J Pediatr Hemaol Oncol 1993; 15(3):346-350.
48. Maliekel K, Rana N, Green D: Recombinant factor VIIa in the management of a pseudotumor in acquired hemophilia. Haemophilia 1997; 3:54-58.
49. Lindley CM, Sawyer WT, Macik BG, et al. Pharmacokinetics and pharmacdynamics of recombinant factor VIIa. Clin Pharmacol & Ther 1994; 55:638-648.
50. Erhardtsen E, Girard P, Nony P, Bech RM, Hedner U, Boissel JP: Pharmacokinetics of recombinant factor VIIa in healthy volunteers pretreted with acenocoumatol. Thrombos Haemostas 1997; Supplementum (Abstract Book), Abstract PS901.
51. 1+2 in patients with a bleeding tendency. Blood Coagtibrinol 1998; 9:S129-S134.
52. Ingerslev J, Friedman D, Gastineau D, et al.: Major surgery in haemophilia patients with inhibitors using recombinant factor VIIa. Haemostatis 1996; 26 (Suppl 1): 131-134.
53. Ingerslev J, Knudsen L, Hvid I, Tange MR, Fredberg U, Sneppen O: Use of recombinant factor VII in surgery in factor VII deficient patients. Hemophilia 1997; 3:215-218.
54. Bernstein DE et al.: Gastroenterology, in press.
55. Erhardtsen E, Nony P, Ffrench P, et al. Further safety information on the use of factor VIIa (rFVIIa) in acenocoumarol treated volunteers. Thromb Hemostas 1995; 73(6):984, Abstract 325.
56. Kristensen J, Killander A, Hippe E, et al.: Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Hemostasis 1996; 26:159-164.
57. Tengborn L, Petruson B: A patient with Glanzmann thrombostenia and epistaxis successfully treated with recombinant factor VIIa. Thromb Hemostas 1996; 75:981-982.
58. Ciavarella N, Schiavoni M, Valenzano E, Mangini F, Inchingolo F: Use of recombinant factor VIIa (NovoSeven) in he treatment of two patients with type II von Willebrand's disease and an inhibitor against von Willebrand factor. Haemostasis 1996; 26 (Suppl 1):150-154.